ethyl 1-benzyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate

• ChemBase编号: 53850
• 分子式: C14H15NO4
• 平均质量: 261.2732
• 单一同位素质量: 261.10010797
• SMILES: C1(=C(CN(C1=O)Cc1ccccc1)C(=O)OCC)O
• Canonical SMILES: CCOC(=O)C1=C(O)C(=O)N(C1)Cc1ccccc1
• InChI: InChI=1S/C14H15NO4/c1-2-19-14(18)11-9-15(13(17)12(11)16)8-10-6-4-3-5-7-10/h3-7,16H,2,8-9H2,1H3
• InChIKey: IGYRPDIWSYGHMY-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: ethyl 1-benzyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylate
• IUPAC传统名: ethyl 1-benzyl-4-hydroxy-5-oxo-2H-pyrrole-3-carboxylate
• 别名: 1-Benzyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester; 1-Benzyl-4-bydroxy-5-oxo-3-pyrroline-3-carboxylic Acid Ethyl Ester; NSC 229530; EBPC; 2,5-Dihydro-4-hydroxy-5-oxo-1-(phenylmethyl)-1H-pyrrole-3-carboxylic acid ethyl ester; CP-10668; EBPC

登记号

• CAS号: 4450-98-0
• MDL号: MFCD00179167
• PubChem SID: 162058613
• PubChem CID: 54677973

理论计算性质

• Acid pKa: 6.437804
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.1272856
• LogD (pH = 7.4): 0.16871071
• Log P: 1.1747024
• 摩尔折射率: 70.1908 cm^3
• 极化性: 26.70844 Å^3
• 极化表面积: 66.84 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; DMSO: ≥10 mg/mL; Methanol
• 外观: Pale Pink Solid; white powder
• 熔点: 132-134°C

安全信息

• 保存条件: protect from light; Refrigerator
• 保存注意事项: IRRITANT
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22-41
• 安全公开号: 26
• TSCA收录: false
• GHS危险品标识: GHS05; GHS07
• GHS警示词: Danger
• GHS危险声明: H302-H318
• GHS警示性声明: P280-P305 + P351 + P338
• 保存温度: room temp

产品相关信息

• 纯度: ≥98% (HPLC); 95+%
• Empirical Formula (Hill Notation): C14H15NO4

详细说明

Sigma Aldrich - PZ0140

Biochem/physiol Actions
EBPC is an aldose reductase inhibitor; anti-cancer.
Other Notes
air sensitive
Legal Information
Sold for research purposes under agreement from Pfizer Inc.

Toronto Research Chemicals - E320500

A highly specific aldose reductase inhibitor that has been shown to enhance HeLa cell sensitivity to chemotherapeutic drugs.

参考文献

• Mylari, B.L. et al.: J. Med. Chem., 34, 1011 (1991)
• Lee, E. et al.: Anti-Cancer Drugs, 13, 859 (1991)
• Verma, M. et al.: Eur. J. Pharmacol., 584, 213 (1991)